Ask AI
ProCE Banner Activity

Evolving Role of HER2-Directed Antibody–Drug Conjugates in the Management of Patients With Advanced NSCLC

Clinical Thought

In this commentary, an expert addresses the evolving role of targeting HER2 in NSCLC, the importance of testing for HER2 alterations in tumor tissue, and FDA approved and investigational HER2-directed ADCs for patients with HER2-altered NSCLC.

Released: November 05, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Matthew Gubens, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Bicycle, Bristol Myers Squibb, Cardinal Health, Catalyst, Foresight, Genentech/Roche, Johnson & Johnson, Natera, Nuvalent, OncoHost, Regeneron; researcher (paid to institution): Amgen, Johnson & Johnson, Merck, Trizell.